Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Immucor, Inc. (“Immucor” or the “Company”) (Nasdaq: BLUD) for potential breaches of fiduciary duties in connection with their conduct related to the sale of the Company to investment funds managed by TPG Capital in a deal with a fully diluted equity value of about $1.973 billion. Under the terms of the proposed transaction, Immucor shareholders will receive $27 in cash, while, according to Yahoo! Finance, at least one financial analyst has set a price target of $28 for Immucor. The proposed transaction is structured as a tender offer and may be effectuated without a shareholder vote. Request more information now by clicking here: www.faruqilaw.com/BLUD Whether Immucor’s Board of Directors breached their fiduciary duties to the Company’s stockholders by failing to conduct an adequate and fair sales process prior to agreeing to this proposed transaction, whether the proposed transaction undervalues Immucor’s shares and by how much this proposed transaction undervalues the Company to the detriment of Immucor’s shareholders are the key focus of this investigation. Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, through all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm’s clients. If you own common stock in Immucor and wish to obtain additional information, please visit us at www.faruqilaw.com/BLUD or contact Juan E. Monteverde, Esq. either via e-mail at firstname.lastname@example.org or by telephone at (877) 247-4292 or (212) 983-9330. Attorney Advertising. (C) 2011 Faruqi & Faruqi, LLP. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We are happy to discuss your particular case.